UNSPSC 51422512: Hydrocortamate hydrochloride

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H41NO6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9QM8U7R83W, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate hydrochloride but more generally known as hydrocortamate hydrochloride, which bears US NIH Compound Identifier 31312. Most nations, for tariff and trade purposes, schedule hydrocortamate hydrochloride under HS 29372900 and SITC 54153.

As of Q4 2014, HYDROCORTAMATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hydrocortamate hydrochloride bears US NLM identifiers UMLS ID C1445700 and NCI Concept Code C65863. SMILES: CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O.CL.

UNSPSC 51422512 Hydrocortamate hydrochloride is a Commodity code nominally describing a specific corticosteroid pharmaceutical product, but recent state and local procurement activity under this code shows a significant mismatch between the code's abstract designation and the work actually being solicited. The recent opportunities block contains two records: a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI regarding direct-to-manufacturer prescription programs. Neither solicitation addresses hydrocortamate hydrochloride specifically or corticosteroid procurement generally. The code shows minimal relevant recent activity aligned with its nominal scope.

The two posted opportunities reflect broader pharmaceutical procurement and health services contracting by state and local health agencies rather than the targeted acquisition of hydrocortamate hydrochloride. Seminole County's IFB (posted June 30, 2026, response due July 26, 2023) solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas HHS Commission's RFI (posted April 3, 2026) seeks vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI is exploratory and precedes formal solicitation. Neither opportunity targets this Commodity code's specified pharmaceutical ingredient, indicating that the code assignment may not reflect the actual procurement focus or that state and local procurement offices are applying broad pharmaceutical codes across diverse health service categories without precise commodity matching.